Introduction
Venous thromboembolism (VTE) is an important preventable cause of in-hospital death.
1-3 VTE including deep vein thrombosis (DVT) and pulmonary embolism (PE) afflicts an estimated 1,000,000 new cases annually in Europe and the United States, combined. [4] [5] [6] Among survivors, VTE is associated with recurrent events, post-thrombotic syndrome, pulmonary hypertension and bleeding events (as a result of anticoagulant therapy), all of which contribute to the high burden of the disease.
7,8
However, contemporary aspects of VTE presentation, pattern of care, and outcomes are understudied. Published epidemiological studies are generally limited by small size, data age (representing a different era of diagnosis and treatment) 9, 10 or lack of detailed clinical data. 11, 12 Clinical trials have also faced challenges in providing adequate evidence base, with ethical and feasibility issues limiting recruitment for some important conditions (e.g. PE with hemodynamic instability, or VTE among those with recent bleeding), 13 and underrepresentation of many key subgroups (such as the elderly, pregnant patients, and those with high risk of bleeding) that limit the availability and generalizability of the evidence. These issues have led to a growing unmet imperative for evidence from large groups of patients without numerous exclusions. 14 Contemporary information to characterize the modern-day presentation, risk factor profile, treatment and outcomes of patients can inform practice and policy, preventing unnecessary harm, and bringing novel hypotheses for future research and improving quality and outcomes.
15-18
The Registro Informatizado Enfermedad TromboEmbolica (RIETE) is a large prospective registry initiated to address these unmet needs and has been enrolling patients with objectively confirmed VTE since 2001. Several of the resultant studies have provided a better understanding of the epidemiology, 19, 20 common treatment patterns, 21, 22 and outcomes 23, 24 of patients with VTE and the key understudied clinical subgroups. [25] [26] [27] In response to continued and expanding investigations from RIETE, herein we provide an overview of the design, methodology, possible and future directions of the registry.
Methods
RIETE is an ongoing, prospective multicentre multinational observational study of patients with objectively confirmed acute VTE. The registry was originally started in Spain in 2001 with the goal of gathering a large sample of patients with VTE, with specific attention to those excluded from the typical randomized trials of anticoagulant therapy (e.g. those with severe renal insufficiency, liver failure, recent major bleeding, pregnancy, disseminated cancer, thrombocytopenia and the elderly) with an aim to understand their common presentation, management pattern and outcomes, as well as factors associated with better or worse patient outcomes.
The hope was also to use the hypothesis-generating findings to help design new randomized clinical studies.
With successful recruitment of an increasing number and diversity of patients over time, the numbers of retrieved variables and data elements were progressively increased. The platform, including the electronic data entry system, was translated to English from 2006 and the network expanded to other participating centres. As of June 30, 2017, RIETE includes 207 investigators from 179 participating centres. RIETE is registered at Clinicaltrials.gov (NCT: 02832245). Detailed information about participating centres is also available at the registry Web site: https://www.riete.org/.
Patients, Inclusion and Exclusion Criteria
At each participating site, patients are screened by the site investigators and checked for eligibility (►Table 1). All patients are objectively confirmed with acute symptomatic or asymptomatic VTE (i.e. DVT, PE, or both). More recently, in an attempt to similarly understand the presentation, treatment pattern, and outcomes of other thrombotic conditions, RIETE has also started to enrol patients with superficial vein thrombosis, splanchnic vein thrombosis (i.e. thrombosis involves the mesenteric, splenic or portal veins), retinal vein thrombosis and cerebral vein thrombosis. At each participating centre, every attempt is made to enrol consecutive patients and RIETE investigators are committed, by contract agreement, to enrol consecutive patients. Periodic audits of the sites have confirmed consecutiveness. Further, comparison against the Spanish Ministry of Health database has shown that patients in RIETE have similar characteristics to the data from all-comers with VTE in that database. 28 No duplicate entries are permitted and patients who are enrolled in blinded treatment trials are ineligible. Methods of DVT diagnosis include contrast venography, ultrasonography, magnetic resonance or, rarely in the past, presentation and outcomes of VTE, including the aforementioned understudied subgroups. RIETE has recently expanded to collect long-term outcome data, and has broadened its inclusion criteria to enrol other forms of venous thrombosis (such as cerebral vein thrombosis and splanchnic vein thrombosis). The RIETE platform is also being used to conduct pragmatic comparative effectiveness studies, including randomized trials. Future steps would focus on collaboration with additional centres across the world, and efforts to ensure the quality and expansion of the registry. In conclusion, RIETE is a large ongoing registry of patients with VTE and other thrombotic conditions. Its results could be helpful for improving our understanding of the epidemiology, patterns of care and outcomes of patients with thrombotic disease. 
Outcomes
The main outcomes of interest in RIETE include all-cause death, PE-specific death, recurrent DVT, recurrent PE, major bleeding, non-major (but clinically relevant) bleeding, arterial ischemic events (myocardial infarction, ischemic stroke or leg amputation), thrombocytopenia, bone fractures and other side-effects of the prescribed therapies. In recent years, development of post-thrombotic syndrome (since 2008) and chronic thromboembolic pulmonary hypertension (since 2015) are also ascertained in those with reported longterm follow-up (►Table 3). RIETE, by design, does not require universal screening for asymptomatic events.
Follow-up
The minimum follow-up duration for patients in RIETE is at least 3 months. 13 Since 2010, collaborators have been requested to extend follow-up to at least 12 months. As for June 30 2017, a total of 24,828 patients have followed up for at least 12 months and 11,304 for at least 24 months (►Fig. 2).
Ethics
All enrolees provide written or verbal informed consent according to the local ethics protocols of enrolling centres. The institutional review board at each enrolling centre approves participation in RIETE for the site investigators and allows the entry of de-identified patient information into the RIETE database. a weekly basis. In case of identification of several inconsistencies from any enrolling centre, a full audit of all the data from that centre is performed. In addition, trained staffs from S & H Medical Science Service make periodic visits to participating centres and compare the information in a randomly selected sample of patients entered by the site investigators. In the most recent audit, RIETE staff assessed 4,100 randomly chosen records that included 1,230,000 measurements. The data showed 95% overall agreement between the registered information by site investigators and patients' original records (with no difference between key data elements and others, and no specific patterns that undermined a group of variables disproportionately). The audits also included ascertainment of inclusion of consecutive patients via cross-checking by available medical records at enrolling hospitals. investigators have also contributed to studies related to prognostication, including for the simplified PE severity index. 29 Other studies have shown the contemporary trends in hospitalizations, clinical presentation and outcomes of patients with DVT and with PE. 21, 22 With continued enrolment and increase in the number and diversity of collaborating centres, in part via better recognition of the registry by other investigators and in part by active advocacy from existing RIETE investigators and the steering committee, it is expected that the registry continues to provide a greater breadth and depth of information related to presentation, treatment pattern and outcomes of patients with VTE. There are several functions in the usage of registries for cardiovascular conditions [15] [16] [17] including VTE. Registries enable us to look into VTE epidemiology (including hospitalizations, and in many cases outpatients), common treatment patterns, trends, variations in practice and also to address some questions related to comparative effectiveness, especially in areas where randomized trials are unfeasible or unlikely to occur (including efficacy studies related to the oldest old, patients with morbid obesity or severe renal insufficiency, or for conditions where equipoise is questioned because of existing grandfathered therapies, or where enrolment is technically challenging because of the high acuity of medical illness [such as the case of massive PE, disseminated cancer and others]; ►Table 4). [36] [37] [38] [39] [40] [41] [42] Registry data complement the findings from randomized trials and are a critical element for contemporary knowledge generation, and quality control. Findings can reflect on routine practice results for newly approved or existing health interventions and may unravel new signals for benefits or harms that were previously understudied in randomized trials. Further, they can reflect on variations in care, temporal trends over time and adherence to guidelines recommendations, among many other utilities. RIETE encompasses several distinct features 18 compared with other existing and ongoing VTE registries. 10,36-38, 42 The large sample size (to our knowledge, the largest prospective patient-level VTE registry) enables the investigators to study questions that are not feasibly addressed in single-centre studies. 19, 21, [29] [30] [31] Patient enrolment is from many centres with various levels of acuity of care, making it a representative sample and providing opportunities for evaluation of care in ambulatory setting, general hospitals, and centres of excellence. Other future specific areas of interest include (but are not limited to) identification of risk factor profiles related to VTE recurrence that can help determine the duration of anticoagulation, and identification of factors based on VTE presentation and comorbidities that could provide hints at tailored therapy for specific drugs, doses and duration (which would be subsequently tested in trial platforms). RIETE also plans to provide additional empiric evidence on non-vitamin-K antagonist oral anticoagulants. Although such patients are currently under-represented in the registry, in part because of slow uptake of this class in Spain due to reimbursement issues, with increasing enrolment of patients from the rest of the world, and possibility of adjustments in the reimbursement regulations in Spain, we anticipate that the breadth and depth of data related to this class of medications in RIETE will be further enriched. The registry also aims to pay attention to understudied subgroups of patients such as those with splanchnic vein thrombosis, superficial vein thrombosis and others. RIETE is gaining additional information to help better characterize the significance and risk factor profile for long-term complications, such as post-thrombotic syndrome and chronic thromboembolic pulmonary hypertension. Furthermore, unlike several other registries, continuation of the registry over time makes it possible for assessment of temporal trends. Finally, the platform will also bring possibilities for future patient-oriented research investigations related to VTE, including pragmatic intervention trials, 43 and quality improvement initiatives. In fact, some such randomized trials are under way using the RIETE platform. [44] [45] [46] In large part driven by the data from the RIETE and tools created based on original such data, RIETE investigators have also created Web site that provides information related to VTE for physicians and patients, including risk estimation models (http://trombo.info/?lang=en). Also, contrary to some of the other existing registries, despite receiving funding from various groups, RIETE is independently investigator driven. The data are entirely managed by the investigators. The funders (including industry funders) have no rights in reviewing the protocols, abstracts or manuscripts, or about decisions to submit them. Design of the RIETE Registry Bikdeli et al. 221
In conclusion, RIETE is a large existing and ongoing VTE registry. It is expected that RIETE will continue to provide clinical evidence for understudied subgroups with thrombotic disease, and will have more prominent role for facilitation of multicentre (and multinational studies) that could be used for assessment of variations and disparities in care, quality improvement and conducting comparative effectiveness research. The overarching goal is to improve the management of VTE through better understanding of prevention, as well as demographics, comorbidities, treatment patterns and outcomes of patients with VTE.
Source of Funding and Its Roles
RIETE is an investigator-initiated registry. During the first 5 years, it was supported by Red Respira from the Instituto Carlos III, Spain (Red Respira-ISCiii-RTIC-03/11). 13 It has been also supported by Sanofi Spain in Spain and by Bayer Pharma AG for the rest of the world. There is no payment per recruited patient. The main incentive for patients and investigators participating in RIETE is to generate new knowledge to help for better understanding of VTE epidemiology and outcomes. None of the sponsors have had any role in the design of the registry and do not have rights to access the database, or to review or comment on prepublished studies from RIETE.
